Yinjia Biopharm Raises ￥10M in Angel Round

(VCBeat) Feb. 10, 2021 -- Yinjia (Shanghai) Biopharmaceuticals Co., Ltd. ("Yinjia Biopharm"), dedicated to developing core raw materials and cutting-edge adjuvant diagnostic products upstream, announced today that it has raised tens of millions in angel round financing, led by CDH Investments, with participation from Furong Capital.

Established in Shanghai Pilot Free Trade Zone Lin-Gang Special Area in 2020, Yinjia Biopharm has set up R&D and production bases in Shanghai, Beijing, and Suzhou. It is a technology platform company focusing on multi-level protein applications, which is committed to original innovation with a combination of international import and cooperation. Through deep cooperation with internationally leading scholars and research institutes, Yinjia Biopharm is engaged in the development, production, and sales of protein raw materials and reagents for the national and global markets.

At the same time, on the basis of its platform, Yinjia Biopharm has developed reagents of core proteins for early diagnosis of tumors, personalized medication guidance, adjuvant tumor immunotherapy, and cell therapy.

Established in 2002, CDH is one of the leading alternative investment fund managers focused on China today with over US$19 billion of assets under management, as of February 31, 2020. From its roots in private equity, CDH has expanded to become a diversified alternative asset management platform covering: Private Equity, Real Assets, Venture and Growth Capital, Mezzanine & Credit, Public Equities and Wealth Management.

Furong Capital is initiated by the Ningbo Institute of Fudan University as a platform for finance, innovation, and entrepreneurship of science and technology. The company actively serves for the regional planning of Yangtze River Delta and the construction of a world-influential science and technology innovation center in Shanghai. Furong Capital focuses on investments in life science and healthcare, integrated circuits, new energy, new materials in the early or mid-term stage.